A limited supply of Nvidia’s chips has reportedly left its customers frustrated. “The demand on it is so great, and everyone wants to be first and everyone wants to be best,” Jensen Huang, CEO of the nearly $3 trillion company, said Wednesday (Sept. 11). “We probably have more emotional customers...
OpenAI is reportedly set to release “Strawberry,” an advanced AI model, sparking excitement — and curiosity — about its potential to advance machine reasoning. This new artificial intelligence system represents OpenAI’s latest foray into machine reasoning. Unlike its predecessors, Strawberry is designed to tackle unfamiliar...
Credo AI has debuted its generative artificial intelligence (AI) vendor registry, letting firms more easily greenlight AI vendors. The company, which provides AI governance software, announced the registry Tuesday (Sept. 10), noting that it comes with pre-populated data for leading AI vendors and developers, such...
The Commerce Department’s Bureau of Industry and Security (BIS) aims to require the world’s leading artificial intelligence (AI) developers and cloud providers to provide detailed reporting to the federal government. The BIS released a Notice of Proposed Rulemaking Monday (Sept. 9), saying that the new...
In a whirlwind week for AI, OpenAI co-founder Ilya Sutskever’s new venture secured $1 billion for ‘safe’ superintelligence, while AI-driven drug discovery hit roadblocks in clinical trials. Meanwhile, tech giants raced to perfect multilingual chatbots, researchers mined big data for insights, and a breakthrough in...
A three-month-old artificial intelligence (AI) startup’s eye-popping $1 billion funding round could signal a shift in how the technology affects commerce. Safe Superintelligence (SSI), co-founded by former OpenAI chief scientist Ilya Sutskever, has secured this massive investment with only 10 employees. The company, launched in...
As artificial intelligence (AI) promises to remake drug discovery, recent clinical trial results reveal its potential and challenges. Recursion Pharmaceuticals, a self-described “clinical stage TechBio company,” recently announced results from its Phase 2 SYCAMORE trial for REC-994, a drug candidate targeting cerebral cavernous malformation (CCM),...
OpenAI executives are reportedly considering subscription prices as high as $2,000 per month for the company’s upcoming large language models (LLMs) like Strawberry and Orion. The executives have discussed higher prices in early internal talks regarding these LLMs, Reuters reported Thursday (Sept. 5), citing a...
Google’s virtual try-on tool now lets shoppers see how they’d look in dresses. The tech giant on Thursday (Sept. 5) announced it is expanding the artificial intelligence (AI)-powered offering to cover dresses, one of its most-searched apparel categories. “This feature is made possible thanks to a generative...
